GC
Kintor Pharma sets Hong Kong IPO in motion
China-based Kintor Pharmaceutical has kicked off bookbuilding for its Hong Kong listing, the latest in a stream of healthcare IPOs in the city. The issuer is targeting HK$1.86bn ($240.1m) in proceeds.
Huatai Financial, the sole sponsor and a joint global co-ordinator alongside CICC and UBS, began taking orders for the offering on Tuesday in Hong Kong.
The trio, alongside five other bookrunners, are marketing a float of 92.3m shares with price guidance of HK$17.80 to HK$20.15 a share. The ...Already a subscriber? Login
